ArQule announces initiation of clinical programs with ARQ 197 in germ cell tumors and colorectal cancer
from BusinessWire via MarketWatch
ArQule, Inc. announced the initiation of a Phase 2, single agent trial with ARQ 197 in germ cell tumors (GCT), including testicular and non-central nervous system tumors, and a Phase 1/2 clinical trial designed to evaluate the safety of ARQ 197 administered in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer who possess the wild-type form of the KRAS gene.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063